Fate Therapeutics' Q2 Loss Widens Amid R&D Surge

TL;DR

**FATE's burning cash faster, but it's a necessary gamble on their pipeline; hold if you believe in the science, otherwise, it's a risky bet.**

AI Summary

FATE THERAPEUTICS INC reported a net loss of $62.3 million for the three months ended June 30, 2025, a significant increase from the $50.1 million net loss in the prior-year period. Revenue for the three months ended June 30, 2025, was $10.5 million, primarily from collaboration agreements, compared to $12.8 million for the same period in 2024, representing a 17.9% decrease. Research and development expenses increased to $55.8 million for the three months ended June 30, 2025, up from $48.2 million in the prior-year period, reflecting continued investment in their pipeline, including FT836. The company's strategic outlook focuses on advancing its iPSC product candidates, with ongoing clinical trials for several programs. Key risks include the substantial net losses incurred since inception, totaling $2.1 billion as of June 30, 2025, and the need for additional capital to fund operations beyond the next 12 months. The company maintains a cash position of $350.2 million as of June 30, 2025, which is expected to fund operations into the second half of 2026.

Why It Matters

FATE's widening net loss and increased R&D spending signal a critical juncture for investors, highlighting the high-risk, high-reward nature of biotech. For employees, continued investment in programs like FT836 offers job security and potential for scientific breakthroughs. Customers, particularly patients awaiting innovative cell therapies, are directly impacted by the pace and success of these R&D efforts. In the competitive landscape of allogeneic cell therapy, FATE's ability to translate its pipeline into commercial products will determine its long-term viability and market share against larger pharmaceutical players.

Risk Assessment

Risk Level: high — The company has incurred substantial net losses since inception, totaling $2.1 billion as of June 30, 2025, and reported a net loss of $62.3 million for the three months ended June 30, 2025. This consistent lack of profitability, coupled with a projected need for additional capital to fund operations beyond the second half of 2026, indicates a high financial risk.

Analyst Insight

Investors should closely monitor FATE's clinical trial progress and cash burn rate. Consider holding if you have a high-risk tolerance and conviction in their iPSC platform, but be prepared for potential dilution from future capital raises. New investors should approach with caution, given the significant financial risks.

Financial Highlights

revenue

$10.5 million

net Income

-$62.3 million

cash Position

$350.2 million

revenue Growth

-17.9%

Revenue Breakdown

Key Numbers

• $62.3 million — Net Loss (for the three months ended June 30, 2025, an increase from $50.1 million in the prior-year period.)
• $10.5 million — Revenue (for the three months ended June 30, 2025, a 17.9% decrease from $12.8 million in the prior-year period.)
• $55.8 million — Research and Development Expenses (for the three months ended June 30, 2025, up from $48.2 million in the prior-year period.)
• $2.1 billion — Accumulated Net Losses (since inception through June 30, 2025.)
• $350.2 million — Cash and Cash Equivalents (as of June 30, 2025, expected to fund operations into the second half of 2026.)

Key Players & Entities

• FATE THERAPEUTICS INC (company) — filer of the 10-Q
• Ono Pharmaceutical Company, Ltd. (company) — collaboration partner
• California Institute for Regenerative Medicine (company) — grant provider for FT836
• FT836 (product) — iPSC product candidate
• Amended MSK License (agreement) — licensing agreement

FAQ

Risk Factors

• Sustained Net Losses and Need for Capital [high — financial]: The company has incurred substantial net losses since inception, totaling $2.1 billion as of June 30, 2025. This ongoing deficit, coupled with a cash position expected to fund operations into the second half of 2026, highlights a significant need for future capital to sustain operations.
• Pipeline Development and Clinical Trial Execution [medium — operational]: Continued investment in the pipeline, including FT836, led to an increase in R&D expenses to $55.8 million for the three months ended June 30, 2025. The success of these programs hinges on effective clinical trial execution and regulatory approvals.
• Biotechnology Regulatory Landscape [high — regulatory]: As a biotechnology company, Fate Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays or failures in obtaining regulatory approvals for its iPSC product candidates could materially impact its business and financial condition.
• Competition in Cell Therapy [medium — market]: The cell therapy market is highly competitive, with numerous companies developing similar or alternative treatment modalities. Fate Therapeutics faces competition from established pharmaceutical companies and emerging biotechs, which could affect market share and pricing power.

Industry Context

The biotechnology sector, particularly in cell therapy, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Fate Therapeutics are at the forefront of developing innovative treatments, but face intense competition and the inherent risks of clinical development.

Regulatory Implications

Fate Therapeutics operates within a heavily regulated industry. Successful navigation of FDA approval processes for its iPSC product candidates is critical. Any delays or setbacks in regulatory reviews could significantly impact the company's ability to bring its therapies to market and generate revenue.

What Investors Should Do

1. Monitor cash burn and runway
2. Evaluate R&D progress and clinical trial updates
3. Assess partnership and collaboration developments

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing a net loss of $62.3 million and revenue of $10.5 million.
• 2025-08-12: Filing Date of 10-Q — The company officially submitted its quarterly report to the SEC.

Glossary

iPSC

Induced pluripotent stem cells. These are adult cells that have been reprogrammed back into an embryonic-like pluripotent state, meaning they can develop into many different cell types in the body. (Fate Therapeutics focuses on developing therapies from iPSC-derived immune cells, making this a core technology for their product pipeline.)

FT836

A specific product candidate in Fate Therapeutics' pipeline, likely an engineered cell therapy. (Mentioned as a key area of investment in R&D, indicating its importance to the company's future prospects.)

Collaboration Agreements

Contracts between companies where they agree to work together on a project, often involving revenue sharing or milestone payments. (This is the primary source of revenue for Fate Therapeutics, highlighting their reliance on partnerships.)

Accumulated Net Losses

The total net loss a company has incurred since its inception, representing the cumulative deficit. (The $2.1 billion accumulated net loss underscores the long-term financial challenges and the need for substantial future funding.)

Year-Over-Year Comparison

For the three months ended June 30, 2025, Fate Therapeutics reported a net loss of $62.3 million, an increase from $50.1 million in the prior-year period. Revenue saw a decrease of 17.9% to $10.5 million compared to $12.8 million in the same period last year. Research and development expenses rose to $55.8 million from $48.2 million, indicating continued investment in pipeline development despite the revenue decline and widening net loss.

Key Financial Figures

• $0.001 — he registrant's common stock, par value $0.001 per share, were issued and outstanding.

Filing Documents

• fate-20250630.htm (10-Q) — 2766KB
• fate-ex10_2.htm (EX-10.2) — 48KB
• fate-ex31_1.htm (EX-31.1) — 13KB
• fate-ex32_1.htm (EX-32.1) — 8KB
• 0000950170-25-107309.txt ( ) — 11947KB
• fate-20250630.xsd (EX-101.SCH) — 1294KB
• fate-20250630_htm.xml (XML) — 2862KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 5 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 79 Item 3. Defaults Upon Senior Securities 79 Item 4. Mine Safety Disclosures 79 Item 5. Other Information 79 Item 6. Exhibits 81

SIGNATURES

SIGNATURES 83 2 RISK FACTOR SUMMARY Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading "Risk Factors" and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission (SEC) before making investment decisions regarding our common stock. Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. If we fail to complete the preclinical or clinical development of, or to obtain regulatory approval for, our product candidates on a timely basis or at all, our business would be significantly harmed. Development of our product candidates will require substantial additional funding, which, if available, may cause dilution to our stockholders, and without which we will be unable to complete preclinical or clinical development of, or obtain regulatory approval for, our product candidates. Additionally, we may not be able to secure adequate funding on acceptable terms or on a timely basis. Our proprietary induced pluripotent stem cell (iPSC) product platform enables the production of next-generation product candidates, and we have multiple iPSC-derived cell product candidates currently undergoing clinical development. We may elect to deprioritize or discontinue the clinical development of one or more of our product candidates for any number of reasons, including due to our prioritization of product can

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Condensed Consolidated Financ ial Statements (Unaudited)

Item 1. Condensed Consolidated Financ ial Statements (Unaudited) Fate Therapeutics, Inc. Condensed Consolida ted Balance Sheets (in thousands, except share and per share data) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 41,249 $ 36,056 Accounts receivable 1,395 3,539 Short-term investments 181,581 243,012 Prepaid expenses and other current assets 6,172 9,302 Total current assets 230,397 291,909 Long-term investments 26,097 27,657 Property and equipment, net 61,097 64,384 Operating lease right-of-use assets 43,814 46,508 Restricted cash 10,227 10,227 Other assets — 9 Total assets $ 371,632 $ 440,694 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,040 $ 9,365 Accrued expenses 18,182 21,348 CIRM award liability, current portion 795 — Deferred revenue — 393 Operating lease liabilities, current portion 5,656 7,416 Total current liabilities 28,673 38,522 CIRM award liability, net of current portion 5,600 5,070 Operating lease liabilities, net of current portion 75,675 77,849 Stock price appreciation milestones 320 527 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.001 par value; authorized shares— 5,000,000 at June 30, 2025 and December 31, 2024; Class A Convertible Preferred shares issued and outstanding— 2,755,086 at June 30, 2025 and December 31, 2024 3 3 Common stock, $ 0.001 par value; authorized shares— 350,000,000 at June 30, 2025 and 250,000,000 at December 31, 2024; issued and outstanding— 114,655,067 at June 30, 2025 and 113,928,279 at December 31, 2024 115 114 Additional paid-in capital 1,730,869 1,716,335 Accumulated other comprehensive income 62 268 Accumulated deficit ( 1,469,685 ) ( 1,397,994 ) Total stockholders' equity 261,364 318,726 Total liabil

View Full Filing

View this 10-Q filing on SEC EDGAR